Roche bids to co-develop potential oral Covid-19 treatment
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment – if approved.
This content was published on
2 minutes
Keystone-SDA/jdp
Português
pt
Roche aposta no desenvolvimento de um tratamento oral contra a Covid-19
The treatment, AT-527, has the potential to become the first oral antiviral to treat Covid-19 patients outside the hospital setting and is also being considered as a preventative measure after Covid-19 exposure. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication.
Phase 2 clinical trials of the treatment in hospitalised patients with moderate Covid-19 infections are underway. A Phase 3 trial with patients outside hospital settings could start next year. As a small and direct-acting oral treatment, it should be possible to manufacture large quantities quickly, Roche says.
“If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems,” indicated Roche in a press release.
The collaboration is expected to help accelerate clinical development and manufacturing in order to make the treatment available to patients as quickly as possible. If AT-527 receives regulatory approval, Atea will be responsible for distributing it in the US, with possible support from Roche subsidiary Genentech. Roche will be responsible for distribution outside the US.
“In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can,” said Bill Anderson, CEO of Roche Pharmaceuticals division.
Roche has been one of the major players in the field of Covid-19 diagnostics and has also been evaluating its existing medicine portfolio for use against the virus. Trials are currently underway to evaluate whether Actemra, approved for use against rheumatoid arthritis, could help patients with severe Covid-19 pneumonia.
In August, the Swiss firm also signed a deal with Regeneron to develop, manufacture, and increase global supply of its antibody cocktail treatment if it is approved for use.
Switzerland abstains from vote on Palestinian bid for full UN membership
This content was published on
On Friday, Switzerland abstained from the vote at the General Assembly on granting the Palestinians new rights at the United Nations (UN).
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche gets approval for coronavirus and flu tests
This content was published on
Swiss firm Roche receives US Emergency Use Authorization for a test to quickly detect whether a patient has Covid-19 or one of two forms of flu.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.